(Press-News.org) Richmond, Va. (Dec. 3, 2010) – Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer (NSCLC) cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
The findings, recently published in Journal of Clinical Investigation, provide the first example of a protein factor regulating the expression of the protein caspase-9, a main player in apoptosis, or programmed cell death. Scientists have known that healthy cells favor caspase-9a, a form of the caspase-9 protein that promotes natural apoptosis. What Chalfant and his research team found is that NSCLC cells favor caspase-9b, which is the anti-apoptotic form of caspase-9 that promotes tumor formation, growth and maintenance. Their further investigation discovered that a protein known as hnRNP L functions as an RNA splicing factor by promoting the expression of caspase-9b through a process known as RNA splicing. While hnRNP L was previously known to have a role in protein expression, its function in relation to cancer biology was unclear until Chalfant's study.
"We're researching an unexplored area of RNA splicing factors in relation to cancer," says Chalfant. "Before this study, there had been very little evidence of an RNA splicing event that results in cancerous tumor development. This study points to caspase-9b as being a very important target in the development of a durable therapy for non-small cell lung cancer."
In mouse models, the researchers used a virus-based targeted gene therapy to reduce the amount of hnRNP L in NSCLC cells. They then observed a lower ratio of caspase-9b to caspase-9a. The result completely stopped the growth of the tumors and had no negative effects on healthy cells. This decrease in the cancer cells' capacity to maintain tumors could make them more susceptible to chemotherapy drugs that typically have little effect on NSCLC.
"Unfortunately, many current therapies for lung cancer are less effective and more toxic than we'd like," says Chalfant. "Lung cancer kills more people than any other cancer, and there is a real need for new cellular targets that are cancer-specific and show results in large numbers of patients regardless of the mutations found in individual tumors. Since caspase-9b is mainly expressed in malignant cells, these findings may provide innovative treatments for non-small cell lung cancer with little to no toxic side effects."
INFORMATION:
Chalfant collaborated on this work with Davis Massey, M.D., D.D.S., Ph.D., at VCU School of Medicine's Department of Pathology and with researchers at VCU School of Medicine's Department of Biochemistry and Molecular Biology and Department of Physiology, as well as with the University of Colorado Cancer Center; the University of Texas Southwestern Medical Center; and the Hunter Holmes McGuire Veterans Administration Medical Center.
The study was supported by grants from the Veteran's Administration, National Institutes of Health, National Cancer Institute, National Aeronautics and Space Agency and International Association for the Study of Lung Cancer as a Young Investigator Award.
The full research article is available at: http://www.jci.org/articles/view/43552/files/pdf.
About VCU Massey Cancer Center: VCU Massey Cancer Center is one of 66 National Cancer Institute-designated institutions that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of cancer clinical trials in Virginia, serving patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
VCU Massey discovery could lead to breakthrough for non-small cell lung cancer
2010-12-04
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Fear of being envied makes people behave well toward others
2010-12-04
It's nice to have success—but it can also make you worry that the jealous people will try to bring you down. New research in Psychological Science, a journal of the Association for Psychological Science, has found that the fear of being the target of malicious envy makes people act more helpfully toward people who they think might be jealous of them.
In previous research, Niels van de Ven of Tilburg University and his colleagues Marcel Zeelenberg and Rik Pieters had figured out that envy actually comes in two flavors: benign envy and malicious envy. They studied people ...
UT Southwestern researchers uncover culprits in life-threatening clotting disorder
2010-12-04
DALLAS – Dec. 3, 2010 – Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.
The findings, available online and in a future issue of The Journal of Clinical Investigation, offer new clues into the mechanisms underlying antiphospholipid syndrome (APS).
"Patients with APS have circulating antibodies that cause exaggerated thrombosis. The longstanding mystery has been how these antibodies initiate ...
Nicotine exposure in pregnant rats puts offspring at risk for learning disabilities
2010-12-04
BIRMINGHAM, Ala. – Exposure to nicotine during pregnancy leads to a decrease in adult stem cells and a change in synaptic plasticity in the hippocampus of the offspring, according to new research from the University of Alabama at Birmingham presented at Neuroscience 2010, the annual Society for Neuroscience meeting in San Diego in November. Researchers say this could be a possible cause for behavioral problems such as attention-deficit hyperactivity disorder (ADHD) seen in children whose mothers smoked.
Adult stem cells in the hippocampus, the area of the brain most connected ...
Electronic cigarettes are unsafe and pose health risks, UC Riverside study finds
2010-12-04
RIVERSIDE, Calif. – Electronic cigarettes (or e-cigarettes), also called "electronic nicotine delivery systems," are increasingly used worldwide even though only sparse information is available on their health effects. In the United States, e-cigarettes are readily available in shopping malls in most states and on the Internet. But how safe are e-cigarettes?
To address this question, researchers at the University of California, Riverside evaluated five e-cigarette brands and found design flaws, lack of adequate labeling, and several concerns about quality control and ...
Snow from space: University of Leicester releases satellite images of snow-bound UK
2010-12-04
Earth observation scientists at the University of Leicester have recorded stunning images of the UK's winter landscape by orbiting satellites.
European Space Agency satellite instruments have been observing the icy blast in the UK from their vantage points in space.
Leicester scientists have used two instruments, MERIS and AATSR, which have returned stunning images of a snow-bound UK from observations on November 29th and December 1st.
In the MERIS images, the colour scale runs from white snow and clouds to green vegetation. In the AATSR images, the non-snow areas ...
Gold and silver nano baubles
2010-12-04
They might just be the smallest Christmas tree decorations ever. Tiny spherical particles of gold and silver that are more than 100 million times smaller than the gold and silver baubles used to decorate seasonal fir trees have been synthesized by researchers in Mexico and the US.
Writing in the December issue of the International Journal of Nanoparticles, materials engineer Xavier E. Guerrero-Dib, of the Universidad Autónoma de Nuevo León and colleagues there and at The University of Texas at Austin, describe the formation of gold, silver and alloyed, bimetallic nanoparticles ...
AGU journal highlights -- Dec. 3, 2010
2010-12-04
The following highlights summarize research papers that have been recently published in Geophysical Research Letters (GRL).
In this release:
Population trends, not climate, causing increased flood fatalities in Africa
Earth's lakes warming in response to climate change
Ozone hole affects upper-atmosphere temperature and circulation
Solar wind contains more oxygen than previously thought
Predicting variability in radiation belt dynamics
Iron oxide observed in Earth's airglow
Anyone may read the scientific abstract for any already-published paper by clicking ...
Onconova to present clinical trials update on ON 01910.Na at American Society of Hematology Meeting
2010-12-04
Estybon® (ON 01910.Na) is a small molecule, targeted therapeutic with a broad spectrum of activity. It has been tested in patients with solid tumors, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at major centers in the U.S. and abroad. MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options for patients, especially those with drug-resistant disease. The presentations will describe the latest results on activity and safety of Estybon® (ON 01910.Na) in MDS and AML patients treated in on-going Phase ...
New observations of exploding stars reveal pauses, flickers and flares not reliably seen before
2010-12-04
Astronomers have traced the waxing and waning light of exploding stars more closely than ever before and seen patterns that aren't yet accounted for in our current understanding of how these eruptions occur.
Using data from a sensitive instrument aboard a satellite that images the entire sky every 102 minutes, they studied four of these stars, or novae, that exploded so violently their light would have been visible without a telescope and measured their brightness over the course of the outburst.
Three of the novae stalled before reaching a peak, and all flickered or ...
GO Markets Upgrades to State of the Art Systems
2010-12-04
GO Markets is pleased to announce the upgrade and replacement of their servers to a new state of the art technology. In light of the growing need for faster and more efficient systems, GO Markets have made the investment and move to a dedicated rack server system. Paul Hill - Managing Director of GO Markets commented on the upgrade and what it would mean for clients.
"...We believe in providing our clients with the most up to date and efficient systems available. The new state of the art HP hardware, will allow for faster processing time, and ultimately faster execution, ...